Table 1

Baseline variables

DemographicsMedical historyMedicationsLab tests
Age, race/ethnicity, sex, lives alone, clinical network, BMI, waist circumference, education, year randomizationPrior CVD event, prior coronary heart failure, diabetes duration, history of neuropathy, peripheral neuropathy, retinal laser/surgery, visual acuity, smoking, depression, blood pressure, electrocardiogramSulfonylureas, metformin, thiazolidinediones, any insulin HCTZ, ACE inhibitors, β-blockers, calcium-channel blockers, fibrates, statins, aspirin, antidepressantsA1C, LDL, HDL, triglyceride, serum creatinine, glomerular filtration rate (modified diet renal disease), urinary albumin-to-creatinine ratio
  • Demographics: age (<65, 65–69, 70–74, ≥75 years), race/ethnicity (Hispanic, white, black, or other), lives alone (vs. with others), clinical center network (7 CCNs), BMI (<30, 30–34, ≥35 kg/m2), waist circumference (<96.7, 96.7–106.6, 106.7–116, ≥116.1 cm), education (<high school, high-school graduate, attended some college or technical school, college graduate), year of randomization into ACCORD (2001–2005). Medical history: diabetes duration (0–5, 6–10, 11–15, ≥16 years), history of neuropathy/nerve problems (“Has the participant ever been told by a physician that he or she has neuropathy/nerve problems”: yes/no), peripheral neuropathy (pedal amputation or a score >2 on the clinical examination portion of the MNSI), visual acuity (<20/40, 20/20–20/40, ≥20/20), smoking status (current, former, never), blood pressure (<135, ≥135), electrocardiogram selected variables (any gross abnormalities, evidence of prior infarction, Q-T interval on electrocardiogram corrected for heart rate [QTc]). Medication use: yes/no at baseline. Laboratory variables: A1C (<7.5, 7.5–8.4, ≥8.5%), LDL cholesterol (<100, 100–119, ≥120 mg/dl), HDL cholesterol (quartiles, mg/dl), triglycerides (<300, ≥300 mg/dl), serum creatinine (0.1–1.0, >1 mg/dl), glomerular filtration rate (modified diet renal disease) (quartiles ml/min), urinary albumin-to-creatinine ratio (<30, 30–300, ≥300 mg/g). HCTZ, hydrochlorotiazide.